Trial Arms and Cohorts

Treatment Arms

The below trial arms and cohorts are currently open to recruitment

Trial arms and cohorts currently open to recruitment
 ArmInvestigational Medicinal Products Cohort Number NSCLC HistologyMolecular Cohort
B Vistusertib  – MTORC-1/2 Inhibitor B2 NSCLC STK11/LKB1 mutation or homozygous deletion
C Palbociclib – CDK-4/6 Inhibitor C1 SCC p16 (CDKN2A) loss of function with proficient Rb
    C3 NSCLC CDK4 amplification with proficient Rb
    C4 NSCLC CCND1 amplification with proficient Rb
    C5 NSCLC
  • STK11/LKB1 mutation or homozygous deletion, or TSC1/2 mutation AND
  • Activated KRAS/MAPK pathway i.e. concomitant KRAS, NRAS or NF1 mutation AND
  • Proficient Rb (no loss of Rb function either by mutation or deletion)
D Crizotinib – ALK Inhibitor D1 NSCLC MET amplification
    D3 NSCLC MET exon 14 skipping (splice mutation or deletion)
E Selumetinib – MEK Inhibitor & Docetaxel  E1  SCC  NF1 mutation 
    E2  ADC or NOS NSCLC NF1 mutation
    E3  NSCLC NRAS mutation
J AZD6738 – ATR inhibitor & Durvalumab - PD-L1 Inhibitor J1  NSCLC
  • KRAS mutation
  • STK11/LKB1 successful test result
    NAJ  NSCLC No actionable genetic change for other trial arms

The following trial Arms and Cohorts are now closed to recruitment:

Trial arms and cohorts closed to recruitment
 ArmInvestigational Medicinal Products Cohort Number NSCLC HistologyMolecular Cohort
A AZD4547 – FGFR Inhibitor A1 NSCLC FGFR2/3 mutation
B Vistusertib  – MTORC-1/2 Inhibitor B1 NSCLC TSC1/2 mutation
C Palbociclib – CDK-4/6 Inhibitor C2 ADC or NOS NSCLC p16 (CDKN2A) loss of function with proficient Rb
    C6 NSCLC

KRAS mutation with proficient Rb

(No concomitant STK11/LKB1 mutation or deletion, no PIK3CA mutation or amplification, no PTEN mutation or homozygous deletion, no AKT mutation, no EGFR mutation, no FGFR2/3 mutation, no TSC1/2 mutation, and no HER2 mutation)

D Crizotinib – ALK Inhibitor D2 NSCLC ROS1 gene fusions
F AZD5363 - AKT Inhibitor F1 SCC PIK3CA mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations
    F2 SCC PIK3CA amplification & no KRAS, NF1, NRAS, HRAS or BRAF aberrations 
    F3 NSCLC

PIK3CA mutation or PIK3CA amplification & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (ADC or NOS NSCLC)

PTEN mutation or PTEN loss & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (ADC or NOS NSCLC)

AKT mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (NSCLC)

    F4 SCC PTEN loss or PTEN mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations
G Osimertinib – EGFR mutation positive T790M+ Inhibitor G1 NSCLC EGFR mutation & T790M mutation
H Sitravatinib – VEGFR inhibitor H1 NSCLC RET rearrangements
NA Durvalumab – PD-L1 Inhibitor NA1 NSCLC No actionable genetic change for other trial arms